{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T22:52:39Z","timestamp":1697410359287},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2005,10]]},"DOI":"10.1007\/s11912-005-0063-4","type":"journal-article","created":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T16:21:21Z","timestamp":1180714881000},"page":"364-371","source":"Crossref","is-referenced-by-count":6,"title":["New developments in immunotherapy for non-Hodgkin\u2019s lymphoma"],"prefix":"10.1007","volume":"7","author":[{"given":"John P.","family":"Leonard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard R.","family":"Furman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morton","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"63_CR1","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"P McLaughlin","year":"1998","unstructured":"McLaughlin P, Grillo-Lopez AJ, Link BK, et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16:2825\u20132833.","journal-title":"J Clin Oncol"},{"key":"63_CR2","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1200\/JCO.2005.09.924","volume":"23","author":"TE Witzig","year":"2005","unstructured":"Witzig TE, Vukov AM, Habermann TM, et al.: Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade 1 non-Hodgkin\u2019s lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 2005, 23:1056\u20131058.","journal-title":"J Clin Oncol"},{"key":"63_CR3","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1200\/JCO.2005.08.128","volume":"23","author":"G Martinelli","year":"2005","unstructured":"Martinelli G, Laszlo D, Ferreri AJ, et al.: Clinical activity of rituximab in gastric marginal zone non-Hodgkin\u2019s lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol 2005, 23:1979\u20131983.","journal-title":"J Clin Oncol"},{"key":"63_CR4","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1023\/A:1008389119525","volume":"10","author":"LD Piro","year":"1999","unstructured":"Piro LD, White CA, Grillo-Lopez AJ, et al.: Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin\u2019s lymphoma. Ann Oncol 1999, 10:655\u2013661.","journal-title":"Ann Oncol"},{"key":"63_CR5","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","volume":"18","author":"TA Davis","year":"2000","unstructured":"Davis TA, Grillo-Lopez AJ, White CA, et al.: Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin\u2019s lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000, 18:3135\u20133143.","journal-title":"J Clin Oncol"},{"key":"63_CR6","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1200\/JCO.2005.12.171","volume":"23","author":"LN Gordan","year":"2005","unstructured":"Gordan LN, Grow WB, Pusateri A, et al.: Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol 2005, 23:1056\u20131058.","journal-title":"J Clin Oncol"},{"key":"63_CR7","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2002.08.674","volume":"20","author":"JD Hainsworth","year":"2002","unstructured":"Hainsworth JD, Litchy S, Burris HA III, et al.: Rituximab as firstline and maintenance therapy for patients with indolent non-Hodgkin\u2019s lymphoma. J Clin Oncol 2002, 20:4261\u20134267.","journal-title":"J Clin Oncol"},{"key":"63_CR8","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood.V95.10.3052","volume":"95","author":"JD Hainsworth","year":"2000","unstructured":"Hainsworth JD, Burris HA III, Morrissey LH, et al.: Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 2000, 95:3052\u20133056.","journal-title":"Blood"},{"key":"63_CR9","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","volume":"103","author":"S Ghielmini","year":"2004","unstructured":"Ghielmini S, Schmitz H, Cogliatts S, et al.: Prolonged treatment with rituximab significantly improves event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004, 103:4416\u20134423. Randomized trial demonstrating benefit of \u2018extended induction\u2019 therapy with rituximab.","journal-title":"Blood"},{"key":"63_CR10","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","volume":"23","author":"JD Hainsworth","year":"2005","unstructured":"Hainsworth JD, Litchy S, Shaffer DW, et al.: Maximizing therapeutic benefit of rituximab: maintenance therapy versus retreatment at progression in patients with indolent non-Hodgkin\u2019s lymphoma: a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005, 23:1088\u20131095. Randomized trial demonstrating that either rituximab maintenance or rituximab retreatment at progression results in similar \u2018duration of rituximab benefit.\u2019","journal-title":"J Clin Oncol"},{"key":"63_CR11","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1200\/JCO.2004.04.020","volume":"22","author":"MS Czuczman","year":"2004","unstructured":"Czuczman MS, Weaver R, Alkuzweny B, et al.: Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin\u2019s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004, 22:4711\u20134716.","journal-title":"J Clin Oncol"},{"key":"63_CR12","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1200\/JCO.2005.02.172","volume":"23","author":"MS Czuczman","year":"2005","unstructured":"Czuczman MS, Koryzna A, Mohr A, et al.: Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 2005, 23:694\u2013704.","journal-title":"J Clin Oncol"},{"key":"63_CR13","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1200\/JCO.2005.05.004","volume":"23","author":"JD Hainsworth","year":"2005","unstructured":"Hainsworth JD, Litchy S, Morrissey LH, et al.: Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin\u2019s lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005, 23:1500\u20131506.","journal-title":"J Clin Oncol"},{"key":"63_CR14","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2004.07.170","volume":"22","author":"PL Zinzani","year":"2004","unstructured":"Zinzani PL, Pulsoni A, Perrotti A, et al.: Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol 2004, 22:2654\u20132661.","journal-title":"J Clin Oncol"},{"key":"63_CR15","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","volume":"105","author":"R Marcus","year":"2005","unstructured":"Marcus R, Imrie K, Belch A, et al.: CVP chemotherapy plus rituximab compared to CVP as first-line treatment for advanced follicular lymphoma. Blood 2005, 105:1417\u20131423. First randomized trial demonstrating benefit of rituximab plus chemotherapy versus chemotherapy alone as initial treatment for indolent lymphoma.","journal-title":"Blood"},{"key":"63_CR16","first-page":"564","volume":"22","author":"P McLaughlin","year":"2003","unstructured":"McLaughlin P, Rodriguez MA, Hagemeister FB, et al.: Stage IV indolent lymphoma: a randomized study of concurrent vs. sequential use of FND chemotherapy (fludarabine, mitoxantrone, dexamethasone) and rituximab (R) monoclonal antibody therapy, with interferon maintenance [abstract 2269]. Proc ASCO 2003, 22:564.","journal-title":"Proc ASCO"},{"key":"63_CR17","first-page":"556","volume":"23","author":"H Hochster","year":"2004","unstructured":"Hochster H, Weller E, Ryan T, et al.: Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL) [abstract 6502]. Proc ASCO 2004, 23:556.","journal-title":"Proc ASCO"},{"key":"63_CR18","doi-asserted-by":"crossref","first-page":"169a","DOI":"10.1182\/blood.V104.11.169.169","volume":"104","author":"MHJ Oers Van","year":"2004","unstructured":"Van Oers MHJ, Van Glabbeke M, Teodorovic I, et al.: Chimeric anti-CD20 monoclonal antibody (Rituximab, Mabthera) in remission induction and maintenance treatment of relapsed\/ resistant follicular non-Hodgkin\u2019s lymphoma: a phase III randomized Intergroup clinical trial. Blood 2004, 104:169a.","journal-title":"Blood"},{"key":"63_CR19","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, et al.: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:235\u2013242.","journal-title":"N Engl J Med"},{"key":"63_CR20","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","volume":"23","author":"P Feugier","year":"2005","unstructured":"Feugier P, Van Hoof A, Sebban C, et al.: Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d\u2019Etude des Lymphomes de L\u2019Adulte. J Clin Oncol 2005, 23:4117\u20134126. Update of first study showing survival benefit of R-CHOP chemotherapy in aggressive NHL.","journal-title":"J Clin Oncol"},{"key":"63_CR21","doi-asserted-by":"crossref","first-page":"48a","DOI":"10.1182\/blood.V104.11.48.48","volume":"104","author":"M Pfreundschuh","year":"2004","unstructured":"Pfreundschuh M, Truemper L, Gill D, et al.: First analysis of the completed Mabthera international (MinT) trial in young patients with low-risk diffuse large B-cell lymphoma (DLBCL): Addition of rituximab to a CHOP-like regimen significantly improves outcome of all patients with the identification of a very favorable subgroup with IPI=0 and no bulky disease. Blood 2004, 104:48a.","journal-title":"Blood"},{"key":"63_CR22","first-page":"8","volume":"102","author":"TM Habermann","year":"2003","unstructured":"Habermann TM, Weller E, Morrison P, et al.: Phase III trial of tituximab-CHOP (R-CHOP) vs. CHOP with a second randomization to maintenance rituximab (MR) or observation in patients 60 years of age and older with diffuse large B-cell lymphoma (DLBCL) [abstract]. Blood 2003, 102:8.","journal-title":"Blood"},{"key":"63_CR23","first-page":"127","volume":"104","author":"TM Habermann","year":"2004","unstructured":"Habermann TM, Weller E, Morrison P, et al.: Rituximab-CHOP versus CHOP with or without maintenance rituximab in patients 60 years of age or older with diffuse large B-cell lymphoma (DLBCL) [abstract]. Blood 2004, 104:127.","journal-title":"Blood"},{"key":"63_CR24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1182\/blood-2003-11-4077","volume":"104","author":"W Wilson","year":"2004","unstructured":"Wilson W, Dunleavy K, Pittaluga S, et al.: Dose-adjusted EPOCH-rituximab is highly effective in the GCB and ABC subtypes of untreated diffuse large B-cell lymphoma [abstract]. Blood 2004, 104:159.","journal-title":"Blood"},{"key":"63_CR25","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/blood-2004-08-3300","volume":"105","author":"M Spina","year":"2005","unstructured":"Spina M, Jaeger U, Sparano JA, et al.: Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin\u2019s lymphoma: pooled results from 3 phase 2 trials. Blood 2005, 105:1891\u20131897.","journal-title":"Blood"},{"key":"63_CR26","doi-asserted-by":"crossref","first-page":"4561","DOI":"10.1200\/JCO.2004.05.035","volume":"22","author":"AL Hoerr","year":"2004","unstructured":"Hoerr AL, Gao F, Hidalgo J, et al.: Effects of pretransplantation treatment with rituximab on outcomes of autologous stemcell transplantation for non-Hodgkin\u2019s lymphoma. J Clin Oncol 2004, 22:4561\u20134566.","journal-title":"J Clin Oncol"},{"key":"63_CR27","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1200\/JCO.2005.08.012","volume":"23","author":"IF Khouri","year":"2005","unstructured":"Khouri IF, Saliba RM, Hosing C, et al.: Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapse aggressive B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol 2005, 23:2240\u20132247.","journal-title":"J Clin Oncol"},{"key":"63_CR28","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1200\/JCO.2005.04.164","volume":"23","author":"M Ghielmini","year":"2005","unstructured":"Ghielmini M, Schmitz SF, Cogliatti S, et al.: Effect of singleagent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2005, 23:705\u2013711.","journal-title":"J Clin Oncol"},{"key":"63_CR29","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"G Lenz","year":"2005","unstructured":"Lenz G, Dreyling M, Hoster E, et al.: Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005, 23:1984\u20131992.","journal-title":"J Clin Oncol"},{"key":"63_CR30","doi-asserted-by":"crossref","first-page":"6a","DOI":"10.1182\/blood-2004-04-1495","volume":"104","author":"MH Dreyling","year":"2004","unstructured":"Dreyling MH, Lenz G, Schiegnitz E, et al.: Early consolidation with myeloablative radiochemotherapy followed by autologous stem cell transplantation significantly prolongs progression-free survival in mantle cell lymphoma: long-term followup of a prospective randomized trial of the European MCL Network [abstract]. Blood 2004, 104:6a.","journal-title":"Blood"},{"key":"63_CR31","doi-asserted-by":"crossref","first-page":"40a","DOI":"10.1182\/blood-2003-10-3400","volume":"104","author":"JE Romaguera","year":"2004","unstructured":"Romaguera JE, Fayad L, Rodriguez MA, et al.: Rituximab plus hypercvad (R-HCVAD) alternating with rituximab plus high dose methotrexate-cytarabine (R-M\/A) in untreated mantle cell lymphoma (MCL): prolonged follow-up confirms high rates of failure-free survival (FFS) and overall survival (OS) [abstract]. Blood 2004, 104:40a.","journal-title":"Blood"},{"key":"63_CR32","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"R Forstpointner","year":"2004","unstructured":"Forstpointner R, Dreyling M, Repp R, et al.: The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004, 104:3064\u20133071.","journal-title":"Blood"},{"key":"63_CR33","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1158\/1078-0432.CCR-1087-3","volume":"10","author":"WL Gluck","year":"2004","unstructured":"Gluck WL, Hurst D, Yuen A, et al.: Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-Hodgkin\u2019s lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin Cancer Res 2004, 10:2253\u20132264.","journal-title":"Clin Cancer Res"},{"key":"63_CR34","first-page":"2534","volume":"22","author":"CF Eisenbeis","year":"2004","unstructured":"Eisenbeis CF, Leonard J, Rosenblatt J, et al.: Conversion of antibody-resistant cancer patients to antibody-sensitive: Investigation of Fc receptor polymorphisms and response to IL-2 and rituximab treatment in rituximab-refractory NHL patients [abstract]. Proc ASCO 2004, 22:2534.","journal-title":"Proc ASCO"},{"key":"63_CR35","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2004-06-2156","volume":"105","author":"JW Friedberg","year":"2005","unstructured":"Friedberg JW, Kim H, McCauley M, et al.: Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha\/beta-inducible gene expression, without significant toxicity. Blood 2005, 105:489\u2013495.","journal-title":"Blood"},{"key":"63_CR36","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1158\/1078-0432.CCR-03-0493","volume":"10","author":"R Stein","year":"2004","unstructured":"Stein R, Qu Z, Chen S, et al.: Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin\u2019s lymphoma. Clin Cancer Res 2004, 10:2868\u20132878.","journal-title":"Clin Cancer Res"},{"key":"63_CR37","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1182\/blood-2004-01-0039","volume":"104","author":"JL Teeling","year":"2004","unstructured":"Teeling JL, French RR, Cragg MS, et al.: Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphoma. Blood 2004, 104:1793\u20131800.","journal-title":"Blood"},{"key":"63_CR38","first-page":"3982S","volume":"9","author":"J Carnahan","year":"2003","unstructured":"Carnahan J, Wang P, Kendall R, et al.: Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res 2003, 9:3982S-90S.","journal-title":"Clin Cancer Res"},{"key":"63_CR39","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1200\/JCO.2003.01.082","volume":"21","author":"JP Leonard","year":"2003","unstructured":"Leonard JP, Coleman M, Ketas JC, et al.: Phase I\/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin\u2019s lymphoma. J Clin Oncol 2003, 21:3051\u20133059.","journal-title":"J Clin Oncol"},{"key":"63_CR40","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.1158\/1078-0432.CCR-04-0294","volume":"10","author":"JP Leonard","year":"2004","unstructured":"Leonard JP, Coleman M, Ketas JC, et al.: Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin\u2019s lymphoma: phase I\/II clinical trial results. Clin Cancer Res 2004, 10:5327\u20135334.","journal-title":"Clin Cancer Res"},{"key":"63_CR41","doi-asserted-by":"crossref","first-page":"7792","DOI":"10.1158\/1078-0432.CCR-04-0756","volume":"10","author":"TA Davis","year":"2004","unstructured":"Davis TA, Kaminski MS, Leonard JP, et al.: The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res 2004, 10:7792\u20137798.","journal-title":"Clin Cancer Res"},{"key":"63_CR42","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2001.19.19.3918","volume":"19","author":"MS Kaminski","year":"2001","unstructured":"Kaminski MS, Zelenetz AD, Press OW, et al.: Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin\u2019s lymphomas. J Clin Oncol 2001, 19:3918\u20133928.","journal-title":"J Clin Oncol"},{"key":"63_CR43","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1182\/blood-2003-11-3883","volume":"103","author":"LI Gordon","year":"2004","unstructured":"Gordon LI, Molina A, Witzig T, et al.: Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ Bcell lymphoma: long-term follow-up of a phase 1\/2 study. Blood 2004, 103:4429\u20134431.","journal-title":"Blood"},{"key":"63_CR44","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","volume":"20","author":"TE Witzig","year":"2002","unstructured":"Witzig TE, Flinn IW, Gordon LI, et al.: Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin\u2019s lymphoma. J Clin Oncol 2002, 20:3262\u20133269.","journal-title":"J Clin Oncol"},{"key":"63_CR45","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1200\/JCO.2005.07.040","volume":"23","author":"SJ Horning","year":"2005","unstructured":"Horning SJ, Younes A, Jain V, et al.: Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 2005, 23:712\u2013719.","journal-title":"J Clin Oncol"},{"key":"63_CR46","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1200\/JCO.2004.06.055","volume":"22","author":"AJ Davies","year":"2004","unstructured":"Davies AJ, Rohatiner AZ, Howell S, et al.: Tositumomab and Iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol 2004, 22:1469\u20131479.","journal-title":"J Clin Oncol"},{"key":"63_CR47","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMoa041511","volume":"352","author":"MS Kaminski","year":"2005","unstructured":"Kaminski MS, Tuck M, Estes J, et al.: I-131 tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005, 352:496\u2013498. Study demonstrating substantial efficacy of single-agent radioimmunotherapy as initial treatment for follicular NHL.","journal-title":"N Engl J Med"},{"key":"63_CR48","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1200\/JCO.2005.05.117","volume":"23","author":"JM Vose","year":"2005","unstructured":"Vose JM, Bierman PJ, Enke C, et al.: Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin\u2019s lymphoma. J Clin Oncol 2005, 23:461\u2013467.","journal-title":"J Clin Oncol"},{"key":"63_CR49","doi-asserted-by":"crossref","first-page":"168a","DOI":"10.1182\/blood.V104.11.583.583","volume":"104","author":"RI Fisher","year":"2004","unstructured":"Fisher RI, LeBlanc M, Press OW, et al.: New treatment options have changed the natural history of follicular lymphoma [abstract 583]. Blood 2004, 104:168a.","journal-title":"Blood"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-005-0063-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11912-005-0063-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-005-0063-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T16:52:11Z","timestamp":1587574331000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11912-005-0063-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["63"],"URL":"https:\/\/doi.org\/10.1007\/s11912-005-0063-4","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,10]]}}}